Soleno Therapeutics INC: management transactions · United States · SEC (Form 4)

About Soleno Therapeutics INC

Soleno Therapeutics Inc. (NASDAQ: SLNO) is a United States-based biopharmaceutical company headquartered in Redwood City, California. For French-speaking investors, Soleno is best understood as a rare-disease specialist whose equity story is built around moving from clinical/regulatory execution into commercialization. The company previously operated under the name Capnia, Inc. and changed its name to Soleno Therapeutics in 2017, underscoring a strategic pivot toward a more focused rare-disease platform. ([stockanalysis.com](https://stockanalysis.com/stocks/slno/company/?utm_source=openai)) Soleno’s core business is the development and commercialization of novel therapies for rare diseases, with a particular emphasis on conditions marked by serious unmet medical need. Its lead asset, VYKAT XR, sits at the center of the investment case and has been the key driver of the company’s transition from a development-stage biotech into a company with commercial ambitions. In its 2024 annual report, Soleno describes itself as a biopharmaceutical company focused on rare diseases and notes that it has divested legacy business efforts in order to concentrate on this core mission. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1484565/000095017025029545/slno-20241231.htm?utm_source=openai)) From a competitive standpoint, Soleno operates in a highly specialized niche where the addressable patient population is small, but clinical differentiation can be economically meaningful. In rare diseases, success depends on more than regulatory approval: commercialization quality, reimbursement access, physician awareness, and post-launch execution all matter materially. That makes Soleno’s market position one of a focused specialist rather than a broad diversified pharma player. The opportunity is attractive precisely because barriers to entry are high and the value of a successful product can be significant relative to the size of the company. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1484565/000095017025029545/slno-20241231.htm?utm_source=openai)) Geographically, Soleno is a U.S. company with operations and corporate headquarters in California, and it is listed on the NASDAQ, giving it visibility among U.S. biotech investors and event-driven market participants. For investors in France, Belgium, and Switzerland, this means SLNO should be viewed as a U.S.-listed healthcare name with the reporting depth of a SEC registrant and the typical volatility profile of a small-cap biotech transitioning toward commercialization. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1484565/000095017025029545/0000950170-25-029545-index.html?utm_source=openai)) Recent developments have been dominated by the company’s regulatory and commercial progress around VYKAT XR. Soleno’s 2024 SEC filing highlighted the FDA’s acceptance of the NDA, priority review designation, and a PDUFA target date of December 27, 2024, marking an important milestone in its path to market. More broadly, recent market coverage suggests that investors increasingly frame Soleno as a commercialization story tied to a lead rare-disease asset, rather than as a purely clinical-stage developer. For equity analysts, the key monitoring points remain product uptake, payer access, regulatory follow-through, and the durability of the launch trajectory. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1484565/000095017025029545/slno-20241231.htm?utm_source=openai))